Details for Patent: 12,622,897
✉ Email this page to a colleague
Which drugs does patent 12,622,897 protect, and when does it expire?
Patent 12,622,897 protects QULIPTA and is included in one NDA.
This patent has seven patent family members in seven countries.
Drugs Protected by US Patent 12,622,897
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-001 | Sep 28, 2021 | RX | Yes | No | 12,622,897 | ⤷ Start Trial | PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS UNDERGOING CONCURRENT TREATMENT WITH AN OATP INHIBITOR | ⤷ Start Trial | ||||
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-002 | Sep 28, 2021 | RX | Yes | No | 12,622,897 | ⤷ Start Trial | PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS UNDERGOING CONCURRENT TREATMENT WITH AN OATP INHIBITOR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,622,897
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2022353124 | ⤷ Start Trial | |||
| Canada | 3234080 | ⤷ Start Trial | |||
| China | 118695859 | ⤷ Start Trial | |||
| European Patent Office | 4408418 | ⤷ Start Trial | |||
| Japan | 2024533756 | ⤷ Start Trial | |||
| Mexico | 2024003952 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2023049920 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
